@article{a25fdc5d95dd429b9c6302b6b7f9025d,
title = "Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy",
abstract = "Aberrant expression of DUX4, a gene unique to humans and primates, causes Facioscapulohumeral Muscular Dystrophy-1 (FSHD), yet the pathogenic mechanism is unknown. As transgenic overexpression models have largely failed to replicate the genetic changes seen in FSHD, many studies of endogenously expressed DUX4 have been limited to patient biopsies and myogenic cell cultures, which never fully differentiate into mature muscle fibers. We have developed a method to xenograft immortalized human muscle precursor cells from patients with FSHD and first-degree relative controls into the tibialis anterior muscle compartment of immunodeficient mice, generating human muscle xenografts. We report that FSHD cells mature into organized and innervated human muscle fibers with minimal contamination of murine myonuclei. They also reconstitute the satellite cell niche within the xenografts. FSHD xenografts express DUX4 and DUX4 downstream targets, retain the 4q35 epigenetic signature of their original donors, and express a novel protein biomarker of FSHD, SLC34A2. Ours is the first scalable, mature in vivo human model of FSHD. It should be useful for studies of the pathogenic mechanism of the disease as well as for testing therapeutic strategies targeting DUX4 expression.",
keywords = "Biomarkers, DUX4, FSHD, Facioscapulohumeral muscular dystrophy, Hypomethylation, Satellite cells, Xenograft, hMPCs",
author = "Mueller, {Amber L.} and Andrea O'Neill and Jones, {Takako I.} and Anna Llach and Rojas, {Luis Alejandro} and Paraskevi Sakellariou and Guido Stadler and Wright, {Woodring E.} and David Eyerman and Jones, {Peter L.} and Bloch, {Robert J.}",
note = "Funding Information: We thank the patients and clinicians of the Wellstone Muscular Dystrophy Cooperative Research Center for FSHD for providing human biopsy samples, and U54HD060848 for the support needed to obtain the biopsies (C. Emerson, PI; K. Wagner, co-I). Additional samples were generously provided by Dr. S. Moore (Wellstone Center, University of Iowa School of Medicine). We are grateful to Dr. A. Cacace and Fulcrum Therapeutics for providing invaluable collaborative support, and to Dr. J. Mauban, Director, Department of Physiology Cyber Confocal Facility (UMB) for technical expertise. We also thank the reviewers for their thoughtful suggestions. This work was funded by NINDS1R21NS086902 (RJB), Friends of FSH Research (RJB), FSH Society (PLJ and RJB), NIA RO1 AG01228 (WEW), NIAMS1R01AR062587 (PLJ), NIAMS5F31AR070621 (ALM), the FSH Society (ALM), and NIGMST32GM08181 (fellowship support for ALM, M. Trudeau and A. Meredith, PIs). Funding Information: We thank the patients and clinicians of the Wellstone Muscular Dystrophy Cooperative Research Center for FSHD for providing human biopsy samples, and U54HD060848 for the support needed to obtain the biopsies (C. Emerson, PI; K. Wagner, co-I). Additional samples were generously provided by Dr. S. Moore (Wellstone Center, University of Iowa School of Medicine). We are grateful to Dr. A. Cacace and Fulcrum Therapeutics for providing invaluable collaborative support, and to Dr. J. Mauban, Director, Department of Physiology Cyber Confocal Facility (UMB) for technical expertise. We also thank the reviewers for their thoughtful suggestions. This work was funded by NINDS 1R21NS086902 (RJB), Friends of FSH Research (RJB), FSH Society (PLJ and RJB), NIA RO1 AG01228 (WEW), NIAMS 1R01AR062587 (PLJ), NIAMS 5F31AR070621 (ALM), the FSH Society (ALM), and NIGMS T32GM08181 (fellowship support for ALM, M. Trudeau and A. Meredith, PIs). Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2019",
month = oct,
doi = "10.1016/j.expneurol.2019.113011",
language = "English (US)",
volume = "320",
journal = "Neurodegeneration",
issn = "0014-4886",
publisher = "Academic Press Inc.",
}